240 related articles for article (PubMed ID: 27072814)
1. Dissecting PUGNAc-mediated inhibition of the pro-survival action of insulin.
Teo CF; El-Karim EG; Wells L
Glycobiology; 2016 Nov; 26(11):1198-1208. PubMed ID: 27072814
[TBL] [Abstract][Full Text] [Related]
2. Identification of a specific inhibitor of nOGA - a caspase-3 cleaved O-GlcNAcase variant during apoptosis.
Li J; Li Z; Li T; Lin L; Zhang Y; Guo L; Xu Y; Zhao W; Wang P
Biochemistry (Mosc); 2012 Feb; 77(2):194-200. PubMed ID: 22348480
[TBL] [Abstract][Full Text] [Related]
3. PUGNAc treatment leads to an unusual accumulation of free oligosaccharides in CHO cells.
Mehdy A; Morelle W; Rosnoblet C; Legrand D; Lefebvre T; Duvet S; Foulquier F
J Biochem; 2012 Apr; 151(4):439-46. PubMed ID: 22337894
[TBL] [Abstract][Full Text] [Related]
4. O-GlcNAc modification on IRS-1 and Akt2 by PUGNAc inhibits their phosphorylation and induces insulin resistance in rat primary adipocytes.
Park SY; Ryu J; Lee W
Exp Mol Med; 2005 Jun; 37(3):220-9. PubMed ID: 16000877
[TBL] [Abstract][Full Text] [Related]
5. Modulation of O-linked N-acetylglucosamine levels on nuclear and cytoplasmic proteins in vivo using the peptide O-GlcNAc-beta-N-acetylglucosaminidase inhibitor O-(2-acetamido-2-deoxy-D-glucopyranosylidene)amino-N-phenylcarbamate.
Haltiwanger RS; Grove K; Philipsberg GA
J Biol Chem; 1998 Feb; 273(6):3611-7. PubMed ID: 9452489
[TBL] [Abstract][Full Text] [Related]
6. An O-GlcNAcase-specific inhibitor and substrate engineered by the extension of the N-acetyl moiety.
Kim EJ; Perreira M; Thomas CJ; Hanover JA
J Am Chem Soc; 2006 Apr; 128(13):4234-5. PubMed ID: 16568991
[TBL] [Abstract][Full Text] [Related]
7. Streptozotocin-induced beta-cell death is independent of its inhibition of O-GlcNAcase in pancreatic Min6 cells.
Gao Y; Parker GJ; Hart GW
Arch Biochem Biophys; 2000 Nov; 383(2):296-302. PubMed ID: 11185566
[TBL] [Abstract][Full Text] [Related]
8. Relationship between protein O-linked glycosylation and insulin-stimulated glucose transport in rat skeletal muscle following calorie restriction or exposure to O-(2-acetamido-2-deoxy-d-glucopyranosylidene)amino-N-phenylcarbamate.
Arias EB; Cartee GD
Acta Physiol Scand; 2005 Mar; 183(3):281-9. PubMed ID: 15743388
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of O-GlcNAcase by a gluco-configured nagstatin and a PUGNAc-imidazole hybrid inhibitor.
Shanmugasundaram B; Debowski AW; Dennis RJ; Davies GJ; Vocadlo DJ; Vasella A
Chem Commun (Camb); 2006 Nov; (42):4372-4. PubMed ID: 17057847
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of O-GlcNAcase using a potent and cell-permeable inhibitor does not induce insulin resistance in 3T3-L1 adipocytes.
Macauley MS; He Y; Gloster TM; Stubbs KA; Davies GJ; Vocadlo DJ
Chem Biol; 2010 Sep; 17(9):937-48. PubMed ID: 20851343
[TBL] [Abstract][Full Text] [Related]
11. A divergent synthesis of 2-acyl derivatives of PUGNAc yields selective inhibitors of O-GlcNAcase.
Stubbs KA; Zhang N; Vocadlo DJ
Org Biomol Chem; 2006 Mar; 4(5):839-45. PubMed ID: 16493467
[TBL] [Abstract][Full Text] [Related]
12. Role of the O-GlcNAc modification on insulin resistance and endoplasmic reticulum stress in 3T3-L1 cells.
Sermikli BP; Aydogdu G; Yilmaz E
Mol Biol Rep; 2020 Aug; 47(8):5927-5942. PubMed ID: 32691273
[TBL] [Abstract][Full Text] [Related]
13. Proteomics and PUGNAcity will overcome questioning of insulin resistance induction by nonselective inhibition of O-GlcNAcase.
Dehennaut V; Lefebvre T
Proteomics; 2013 Oct; 13(20):2944-6. PubMed ID: 23983178
[TBL] [Abstract][Full Text] [Related]
14. Increasing O-GlcNAc levels: An overview of small-molecule inhibitors of O-GlcNAcase.
Macauley MS; Vocadlo DJ
Biochim Biophys Acta; 2010 Feb; 1800(2):107-21. PubMed ID: 19664691
[TBL] [Abstract][Full Text] [Related]
15. Insight into a strategy for attenuating AmpC-mediated beta-lactam resistance: structural basis for selective inhibition of the glycoside hydrolase NagZ.
Balcewich MD; Stubbs KA; He Y; James TW; Davies GJ; Vocadlo DJ; Mark BL
Protein Sci; 2009 Jul; 18(7):1541-51. PubMed ID: 19499593
[TBL] [Abstract][Full Text] [Related]
16. Prolonged incubation in PUGNAc results in increased protein O-Linked glycosylation and insulin resistance in rat skeletal muscle.
Arias EB; Kim J; Cartee GD
Diabetes; 2004 Apr; 53(4):921-30. PubMed ID: 15047606
[TBL] [Abstract][Full Text] [Related]
17. Glucosamine modulates TNF-α-induced ICAM-1 expression and function through O-linked and N-linked glycosylation in human retinal pigment epithelial cells.
Chen CL; Liang CM; Chen YH; Tai MC; Lu DW; Chen JT
Invest Ophthalmol Vis Sci; 2012 Apr; 53(4):2281-91. PubMed ID: 22427561
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of O-GlcNAcase by PUGNAc is dependent upon the oxime stereochemistry.
Perreira M; Kim EJ; Thomas CJ; Hanover JA
Bioorg Med Chem; 2006 Feb; 14(3):837-46. PubMed ID: 16214344
[TBL] [Abstract][Full Text] [Related]
19. Elevated nucleocytoplasmic glycosylation by O-GlcNAc results in insulin resistance associated with defects in Akt activation in 3T3-L1 adipocytes.
Vosseller K; Wells L; Lane MD; Hart GW
Proc Natl Acad Sci U S A; 2002 Apr; 99(8):5313-8. PubMed ID: 11959983
[TBL] [Abstract][Full Text] [Related]
20. Analysis of PUGNAc and NAG-thiazoline as transition state analogues for human O-GlcNAcase: mechanistic and structural insights into inhibitor selectivity and transition state poise.
Whitworth GE; Macauley MS; Stubbs KA; Dennis RJ; Taylor EJ; Davies GJ; Greig IR; Vocadlo DJ
J Am Chem Soc; 2007 Jan; 129(3):635-44. PubMed ID: 17227027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
